Given the high prevalence of the TERT promoter mutations C228T and C250T in cutaneous melanoma [5, 28], their addition to existing tests for detection of mutant BRAF and NRAS will allow monitoring of most melanoma patients using ddPCR. This evidence concerns the gene TERT and melanoma.